| |
Survivors
(
n
= 13)
|
Non-survivors
(
n
= 9)
|
P
value
|
|---|
|
Age, years
|
36.5 ± 14.7
|
60.2 ± 14.9
|
0.001
|
|
Male sex
|
6 (46%)
|
4 (44%)
|
0.64
|
|
Systolic BP, mm Hg
|
84.5 ± 21.7
|
81.4 ± 27.3
|
0.78
|
|
Heart rate, bpm
|
110.0 ± 33.3
|
92.0 ± 26.1
|
0.22
|
|
Presence of pulseless VT or Vf
|
9 (69%)
|
6 (67%)
|
0.90
|
|
LVDd, mm
|
46.0 ± 7.7
|
44.0 ± 5.4
|
0.62
|
|
LVDs, mm
|
40.7 ± 7.3
|
36.4 ± 4.2
|
0.25
|
|
LVEF, %
|
22.9 ± 8.5
|
23.6 ± 12.6
|
0.88
|
|
Laboratory data on admission
|
|
WBC (/μL)
|
10,213.9 ± 5,431.6
|
11,937.8 ± 9,399.0
|
0.59
|
|
GOT (IU/L)
|
768.6 ± 864.1
|
1,599.8 ± 2,759.7
|
0.40
|
|
GPT (IU/L)
|
540.6 ± 726.9
|
1,044.2 ± 1,882.0
|
0.46
|
|
LDH (IU/L)
|
2,187.9 ± 2,198.0
|
2,815.1 ± 4,245.1
|
0.65
|
|
Total-Bil (mg/dL)
|
0.72 ± 0.29
|
0.85 ± 0.49
|
0.46
|
|
Direct-Bil (mg/dL)
|
0.28 ± 0.11
|
0.37 ± 0.31
|
0.36
|
|
BUN (mg/dL)
|
26.7 ± 12.4
|
38.9 ± 29.0
|
0.26
|
|
Creatinine (mg/dL)
|
1.47 ± 0.76
|
1.48 ± 0.98
|
0.99
|
|
Max. CK (IU/L)
|
3,090.2 ± 4,416.1
|
3,148.0 ± 4,456.2
|
0.98
|
|
Max. CK-MB (IU/L)
|
154.9 ± 279.8
|
113.2 ± 70.1
|
0.67
|
- Data are presented as the mean ± standard deviation or as the number of patients (%).
-
BP blood pressure, VT ventricular tachycardia, Vf ventricular fibrillation, LVDd left ventricular end-diastolic dimension, LVDs left ventricular end-systolic dimension, LVEF left ventricular ejection fraction, WBC white blood cell, GOT glutamic oxaloacetic transaminase, GPT glutamic pyruvic transaminase, LDH lactate dehydrogenase, Bil bilirubin, BUN blood urea nitrogen, Max. maximum, CK creatine kinase.
